Last updated on November 2019

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.


Brief description of study

For each dose finding cohorts (A, B, C and D):

The primary objective of each dose finding cohort is to determine the maximum tolerated dose (MTD) / recommended phase II dose (RP2D) of xentuzumab in combination with abemaciclib with or without hormonal therapy (letrozole, anastrozole, fulvestrant). Dose limiting toxicities (DLT) will be assessed during the first treatment cycle to assess the MTD/RP2D.

In case that no MTD is reached a RP2D dose will be determined taking into account safety data and other available information. This will be agreed with the Steering Committee.

For each expansion cohorts (E, F, D1 and D2):

The objectives of the expansion cohorts are to assess the anti-tumour activity of xentuzumab in combination with abemaciclib in patients with non-small cell lung cancer (cohort E).

Tentatively a cohort F may be opened to assess the anti-tumour activity of the triplet combination xentuzumab / abemaciclib and fulvestrant in a single-arm expansion group of patients with locally advanced / metastatic hormone receptor positive (HR+) breast cancer who have progressed following prior aromatase inhibitor therapy and prior CDK4/6 inhibitor treatment. Cohort F will only be opened if indicated by emerging data from ongoing clinical trials.

The primary objective of cohorts D1 and D2 is to assess the anti-tumour activity of the triplet combination xentuzumab, abemaciclib and fulvestrant in patients with locally advanced / metastatic HR+ breast cancer who have progressed on prior endocrine therapy. Cohort D1 will assess the anti-tumour activity for subjects with visceral metastasis and Cohort D2 for subjects with non-visceral metastasis.

Clinical Study Identifier: NCT03099174

Find a site near you

Start Over

INS Curie

Paris, France
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

University of Miami

Miami, FL United States
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Duran i Reynals

L'Hospitalet de Llobregat, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Docrates Clinic

Helsinki, Finland
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Tokai University Hospital

Kanagawa, Isehara, Japan
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

HOP Jean Minjoz

Besançon, France
  Connect »

Ctr Cario

Plerin Sur Mer, France
  Connect »

CTR Paul Strauss

Strasbourg, France
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

HOP Jean Minjoz

Besançon, France
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

HOP Jean Minjoz

Besançon, France
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

HOP Jean Minjoz

Besançon, France
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

HOP Jean Minjoz

Besançon, France
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »

HOP Jean Minjoz

Besançon, France
  Connect »

Hospital Quir nsalud Madrid

Pozuelo de Alarcón, Spain
  Connect »